|Bid||11.630 x 1100|
|Ask||11.640 x 1800|
|Day's Range||11.310 - 11.750|
|52 Week Range||11.310 - 17.620|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As we recently mentioned, biotech stocks have been particularly hammered over the last few weeks. Unfortunately, that’s meant that many biotech stocks have been hit hard. The market rout has caused many biotech stocks to drop to single or low double-digit prices.
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
Inc. said it has agreed to acquire clinical-stage gene therapy company Celenex for $100 million in cash, giving the publicly traded biotechnology company entry into gene therapies. Celenex has licensed a few pivotal and potentially first-to-market gene therapy programs to fight Batten disease, a fatal disorder that affects the nervous system in children. Under the acquisition agreement, Celenex’s shareholders are eligible for up to $277 million if significant development, submission and approval milestones are met, and up to $75 million in tiered sales.
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
In the second quarter, PTC Therapeutics generated revenues of $68.7 million—compared to $48.0 million in the second quarter of 2017, which reflected ~43% growth YoY (year-over-year). In the first half of 2018, PTC Therapeutics reported net revenues of $124.8 million—compared to $74.5 million in the first half of 2017.
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with a net loss of $22.74 million in the second quarter of 2017. That translates to a net loss per share of $0.85 in the second quarter of 2018. Its net loss per share was $0.87 in the second quarter of 2017.
In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.
On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.
Below is a list of notable corporate events for the week beginning August 13. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on NTAP Monday ...
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States. Galafold - approved on Friday by U.S. regulators - is the first new Fabry disease treatment in the country in over 15 years, and will compete with Sanofi SA's infused Fabrazyme, which has an average U.S. list price of $340,000 for adults, according to Amicus. Galafold is an oral therapy for Fabry disease, a sometimes fatal genetic condition in which accumulation of fat damages several organs.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has experienced volatility amid the release of another spate of earnings reports. Even as the earnings season winds down, the upcoming week ...
U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs. Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi SA’s infused Fabrazyme. An estimated 3,000 people in the United States are diagnosed with the disease.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 12.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cranbury, New Jersey-based company said it had a loss of 33 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
The New Jersey based biotech company, Amicus Therapeutics, was founded in 2002 by a father looking to find a cure for his children. Yahoo Finance’s Alexis Christoforous sits down with its founder and CEO, John Crowley.